Baseline characteristics of patients treated in LyMa and LyMa-101 trials before and after PSM
Set . | Before matching (PS set) . | After PSM (matching set) . | Fisher test after PSM,∗ P value . | ||
---|---|---|---|---|---|
Number . | LyMa, n = 296 . | LyMa-101, n = 84 . | LyMa, n = 168 . | LyMa-101, n = 84 . | |
Sex | |||||
Male | 234 (79%) | 61 (73%) | 121 (72%) | 61 (72%) | 1 |
Female | 62 (21%) | 23 (27%) | 47 (28%) | 23 (27%) | |
MIPI risk group | |||||
Low | 157 (53%) | 46 (55%) | 89 (53%) | 46 (54%) | 1 |
Intermediate | 82 (28%) | 24 (28%) | 50 (30%) | 24 (29%) | |
High | 57 (19%) | 14 (17%) | 29 (17%) | 14 (17%) | |
Ann Arbor stage | |||||
II | 18 (6%) | 2 (3%) | 1 (1%) | 2 (2%) | .2 |
III | 30 (10%) | 6 (7%) | 21 (12%) | 6 (7%) | |
IV | 248 (84%) | 76 (90%) | 146 (87%) | 76 (91%) | |
B symptoms | |||||
No | 209 (71%) | 68 (81%) | 139 (83%) | 68 (81%) | .7 |
Yes | 87 (29%) | 16 (19%) | 29 (17%) | 16 (19%) | |
Blastoid variant | |||||
No | 261 (88%) | 70 (83%) | 143 (85%) | 70 (83%) | .7 |
Yes | 35 (12%) | 14 (17%) | 25 (15%) | 14 (17%) |
Set . | Before matching (PS set) . | After PSM (matching set) . | Fisher test after PSM,∗ P value . | ||
---|---|---|---|---|---|
Number . | LyMa, n = 296 . | LyMa-101, n = 84 . | LyMa, n = 168 . | LyMa-101, n = 84 . | |
Sex | |||||
Male | 234 (79%) | 61 (73%) | 121 (72%) | 61 (72%) | 1 |
Female | 62 (21%) | 23 (27%) | 47 (28%) | 23 (27%) | |
MIPI risk group | |||||
Low | 157 (53%) | 46 (55%) | 89 (53%) | 46 (54%) | 1 |
Intermediate | 82 (28%) | 24 (28%) | 50 (30%) | 24 (29%) | |
High | 57 (19%) | 14 (17%) | 29 (17%) | 14 (17%) | |
Ann Arbor stage | |||||
II | 18 (6%) | 2 (3%) | 1 (1%) | 2 (2%) | .2 |
III | 30 (10%) | 6 (7%) | 21 (12%) | 6 (7%) | |
IV | 248 (84%) | 76 (90%) | 146 (87%) | 76 (91%) | |
B symptoms | |||||
No | 209 (71%) | 68 (81%) | 139 (83%) | 68 (81%) | .7 |
Yes | 87 (29%) | 16 (19%) | 29 (17%) | 16 (19%) | |
Blastoid variant | |||||
No | 261 (88%) | 70 (83%) | 143 (85%) | 70 (83%) | .7 |
Yes | 35 (12%) | 14 (17%) | 25 (15%) | 14 (17%) |
In this analysis, 296 and 84 patients in the R and O groups, respectively, were matched based on clinical data at inclusion, resulting in 168 and 84 PSM patients in the R and O groups, respectively. Notably, 5 patients (3 in LyMa trial and 2 in LyMa-101 trial) were excluded from this analysis because of missing data (n = 3 with no MIPI group assessment available) or consent withdrawn (n = 2).
Fisher test was done between matched populations.